Evidence map›Paper›PMID 35163436›Full record

ReviewInternational journal of molecular sciences2022

Role of miRNA-1 and miRNA-21 in Acute Myocardial Ischemia-Reperfusion Injury and Their Potential as Therapeutic Strategy.

Eranthi Jayawardena, Lejla Medzikovic, Gregoire Ruffenach, Mansoureh Eghbali

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
6.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 48 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Epigenetic Mechanisms in Heart Diseases.Reviews in cardiovascular medicine · 2025
    Review
  9. MicroRNAs' Impact on Heart Diseases.International journal of molecular sciences · 2025
    Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Impact of microRNAs on cardiovascular diseases and aging.The Journal of international medical research · 2024
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Eranthi JayawardenaDivision of Molecular Medicine, Department of Anesthesiology, David Geffen School of Medicine at UCLA, BH-550 CHS, Los Angeles, CA 90095, USA.
Lejla MedzikovicDivision of Molecular Medicine, Department of Anesthesiology, David Geffen School of Medicine at UCLA, BH-550 CHS, Los Angeles, CA 90095, USA.
Gregoire RuffenachDivision of Molecular Medicine, Department of Anesthesiology, David Geffen School of Medicine at UCLA, BH-550 CHS, Los Angeles, CA 90095, USA.
Mansoureh EghbaliDivision of Molecular Medicine, Department of Anesthesiology, David Geffen School of Medicine at UCLA, BH-550 CHS, Los Angeles, CA 90095, USA.ORCID 0000-0002-6252-9976
University of California, Los Angeles · US

Funding

Role of miR125 in pulmonary hypertension secondary to interstitial lung diseaseR01HL147586 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI EGHBALI, MANSOUREH · 2020 to 2023
$1.9M
Role of Chromosome Y gene, Uty, in protecting against Pulmonary HypertensionR01HL159865 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI EGHBALI, MANSOUREH · 2021 to 2024
$1.9M
NHLBI NIH HHS R01 HL147586NIH HHS R01HL147586NIH HHS R01HL159865
6 · The paper itself

Abstract

Coronary artery disease remains the leading cause of death. Acute myocardial infarction (MI) is characterized by decreased blood flow to the coronary arteries, resulting in cardiomyocytes death. The most effective strategy for treating an MI is early and rapid myocardial reperfusion, but restoring blood flow to the ischemic myocardium can induce further damage, known as ischemia-reperfusion (IR) injury. Novel therapeutic strategies are critical to limit myocardial IR injury and improve patient outcomes following reperfusion intervention. miRNAs are small non-coding RNA molecules that have been implicated in attenuating IR injury pathology in pre-clinical rodent models. In this review, we discuss the role of miR-1 and miR-21 in regulating myocardial apoptosis in ischemia-reperfusion injury in the whole heart as well as in different cardiac cell types with special emphasis on cardiomyocytes, fibroblasts, and immune cells. We also examine therapeutic potential of miR-1 and miR-21 in preclinical studies. More research is necessary to understand the cell-specific molecular principles of miRNAs in cardioprotection and application to acute myocardial IR injury.

Indexed as

AnimalsGene Expression RegulationGenetic TherapyHumansMicroRNAsMyocardial Reperfusion InjuryTranslational Science, BiomedicalMicroRNAsMIRN1 microRNA, humanMIRN21 microRNA, humancardiomyocytescardioprotectioncardiovascular diseasecoronary artery diseasefibroblastsimmune cellsmiRNA-1 (miR-1)miRNA-21 (miR-21)myocardial infarctionmyocardial ischemia-reperfusion injury

Identifiers

PMID35163436
PMCPMC8836257
OpenAlexW4210380810

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.